Generic Name and Formulations:
Corticorelin ovine (as the trifluoroacetate) 100mcg/vial; pwd for IV inj after reconstitution.
Ferring Pharmaceuticals, Inc.
Indications for ACTHREL:
For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.
Adults and Children:
Testing pituitary corticotrophin function: 1mcg/kg IV as a single dose. ACTH and cortisol response prolonged and remain elevated for up to 2 hours. Doses >1mcg/kg: not recommended. If repeat test needed, do tests at the same time of day as original test.
Higher doses associated with transient tachycardia, decreased BP, loss of consciousness, and asystole; symptoms may be reduced if given as a 30 second IV infusion instead of bolus inj. Pregnancy (Cat.C). Nursing mothers.
Plasma ACTH response inhibited by dexamethasone. Heparin to maintain IV cannula patency: not recommended.
Corticotropin-releasing hormone (CRH) analogue.
Flushing of the face, neck, upper chest; tachycardia, hypotension, dyspnea, chest compression or tightness with higher doses.
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Bariatric Surgery: An Effective Treatment for Type 2 Diabetes
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation